New Immune-Chemo cocktail aims to shrink inoperable lung tumors
NCT ID NCT07082179
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two immune-boosting antibodies (iparomlimab and tuvonralimab) plus chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study will enroll 33 adults who have not had prior treatment. The goal is to see if the treatment can shrink tumors enough to allow surgery or improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab and tuvonralimab (immune-boosting antibodies) plus paclitaxel polymer micelles and platinum chemotherapy (cisplatin or carboplatin)
What this could lead to
If successful, this combination could shrink or control advanced lung cancer tumors, potentially allowing more patients to become candidates for surgery.
What could go wrong
This is a small, early-phase trial with only 33 participants, so results may not apply broadly. The drug combination may cause significant side effects, and it is not yet known if it improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Provincial Cancer Hospital
RECRUITINGNanjing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••